MYELOPEROXIDASE POLYMORPHISM ON ENDOTHELIAL FUNCTION AND VASCULAR COMPLIANCE

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这项研究的目的是确定一种名为“髓过氧化物酶”的基因的自然变异是否在血管功能异常中起作用。众所周知，这种血管异常会影响血压，也会导致心脏问题。这是一项对髓过氧化物酶（MPO）基因的研究，因为医学研究表明，这种基因的某种变化在心脏病患者中更为常见。这是一项血管功能的研究在MPO基因中有这种变异的人和没有这种变异的人之间进行比较。这种比较将使用一种叫做氨苯砜的药物进行。众所周知，氨苯砜可以阻断MPO基因产生的一种名为“髓过氧化物酶”的酶的作用。氨苯砜被FDA批准用于治疗某些皮肤状况，但在本研究中被认为是研究性的。受试者将1)年龄在18 - 45岁之间，没有已知的心脏病危险因素；2)有心脏病危险因素，如高血压、高胆固醇或每天吸烟超过一包20年，a)年龄在45-69岁之间的男性；b)年龄在69岁以下的绝经后女性。受试者将被随机分配接受氨苯砜或安慰剂。本研究的假设是：1)MPO GG基因型与血管功能受损有关，2)GG基因型受试者的血管功能障碍可通过氨苯砜治疗抑制MPO得到改善

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research study is to determine if a natural variation in a gene called "myeloperoxidase" plays a role in the abnormal functioning of blood vessels. It is known that this abnormality of blood vessels affects blood pressure and also leads to heart problems. This is a study of a particular gene, called the myeloperoxidase (MPO) gene, since medical studies have suggested that a certain change in this gene is seen more often in patients with heart disease. This is a study of blood vessel function in people having this variation in the MPO gene compared to a group that does not have the variation. This comparison will be made using a medication called dapsone. Dapsone is known to block the effect of an enzyme called "myeloperoxidase", produced by the MPO gene. Dapsone is approved by the FDA for treatment of certain skin conditions but is considered investigational for the purpose of this study. Subjects will 1) be between 18 and 45 years old and have no known risk factors for heart disaease or 2) have risk factors for heart disease such as high blood pressure, high cholesterol or have smoked more than 1 pack per day for 20 years and are a) male, aged 45-69 years, or b) postmenopausal women, less than 69 years old. Subjects will be randomly assigned to receive dapsone or placebo. The hypotheses of the study are: 1) The MPO GG genotype is associated with impaired vascular function, and 2) vascular dysfunction in subjects with GG genotype is improved by inhibiting MPO with dapsone thera